Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001216750 | SCV001388562 | likely benign | Holocarboxylase synthetase deficiency | 2024-01-25 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001751405 | SCV001996107 | uncertain significance | not provided | 2019-09-18 | criteria provided, single submitter | clinical testing | In silico analysis, which includes protein predictors and evolutionary conservation, supports that this variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Ambry Genetics | RCV002561908 | SCV003658977 | likely benign | Inborn genetic diseases | 2021-07-09 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Natera, |
RCV001216750 | SCV002083719 | uncertain significance | Holocarboxylase synthetase deficiency | 2020-10-06 | no assertion criteria provided | clinical testing |